Merus BV Total Assets
Merus BV total assets. Based on the latest financial reports, Merus BV (MRUS) holds total assets worth $771.99 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Merus BV operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Total Assets of Merus BV (2012–2024)
Total assets of Merus BV from 2012 to 2024. This chart illustrates how Merus BV's total assets have evolved over time, based on quarterly financial data. See Merus BV (MRUS) share price today for real-time trading data and today's change.
Merus BV - Asset Composition Analysis
Merus BV Total Assets Breakdown (December 2024)
Merus BV total assets breakdown as of December 2024. Merus BV's total assets of $771.99 Million consist of 72.5% current assets and 27.5% non-current assets. Explore Merus BV short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.4% |
| Accounts Receivable | $4.71 Million | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.68 Million | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Merus BV's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Merus BV's current assets represent 72.5% of total assets in 2024, a decrease from 85.6% in 2012.
- Cash Position: Cash and equivalents constituted 37.4% of total assets in 2024, down from 73.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 11.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.6% of total assets.
Merus BV Competitors by Total Assets
Key competitors of Merus BV based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
PHARVARIS N.V. EO -12
F:9EN
|
Germany | €301.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.98 Billion |
Merus BV - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.97 | 8.32 | 4.66 |
| Quick Ratio | 7.97 | 8.32 | 4.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $516.65 Million | $586.20 Million | $171.25 Million |
Merus BV - Advanced Valuation Insights
This section examines the relationship between Merus BV's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.81 |
| Latest Market Cap to Assets Ratio | 8.69 |
| Asset Growth Rate (YoY) | 72.4% |
| Total Assets | $785.13 Million |
| Market Capitalization | $6.83 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Merus BV's assets at a significant premium (8.69x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Merus BV's assets grew by 72.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Merus BV (2012–2024)
The table below shows the annual total assets of Merus BV from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $785.13 Million | +72.37% |
| 2023-12-31 | $455.49 Million | +20.97% |
| 2022-12-31 | $376.54 Million | -17.53% |
| 2021-12-31 | $456.60 Million | +97.48% |
| 2020-12-31 | $231.22 Million | -12.21% |
| 2019-12-31 | $263.38 Million | +5.37% |
| 2018-12-31 | $249.96 Million | +5.87% |
| 2017-12-31 | $236.11 Million | +210.47% |
| 2016-12-31 | $76.05 Million | +95.97% |
| 2015-12-31 | $38.81 Million | +801.48% |
| 2014-12-31 | $4.30 Million | -74.91% |
| 2013-12-31 | $17.16 Million | +61.53% |
| 2012-12-31 | $10.62 Million | -- |
About Merus BV
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more